全文获取类型
收费全文 | 45148篇 |
免费 | 3468篇 |
国内免费 | 752篇 |
专业分类
耳鼻咽喉 | 226篇 |
儿科学 | 602篇 |
妇产科学 | 644篇 |
基础医学 | 2166篇 |
口腔科学 | 301篇 |
临床医学 | 5727篇 |
内科学 | 4685篇 |
皮肤病学 | 697篇 |
神经病学 | 1414篇 |
特种医学 | 888篇 |
外国民族医学 | 1篇 |
外科学 | 2607篇 |
综合类 | 4892篇 |
一般理论 | 4篇 |
预防医学 | 6787篇 |
眼科学 | 331篇 |
药学 | 13652篇 |
50篇 | |
中国医学 | 1174篇 |
肿瘤学 | 2520篇 |
出版年
2024年 | 46篇 |
2023年 | 825篇 |
2022年 | 1270篇 |
2021年 | 1859篇 |
2020年 | 1867篇 |
2019年 | 1654篇 |
2018年 | 1598篇 |
2017年 | 1692篇 |
2016年 | 1587篇 |
2015年 | 1727篇 |
2014年 | 3511篇 |
2013年 | 4406篇 |
2012年 | 3293篇 |
2011年 | 3445篇 |
2010年 | 2581篇 |
2009年 | 2393篇 |
2008年 | 2320篇 |
2007年 | 2153篇 |
2006年 | 1845篇 |
2005年 | 1483篇 |
2004年 | 1141篇 |
2003年 | 917篇 |
2002年 | 723篇 |
2001年 | 627篇 |
2000年 | 519篇 |
1999年 | 507篇 |
1998年 | 336篇 |
1997年 | 302篇 |
1996年 | 250篇 |
1995年 | 257篇 |
1994年 | 237篇 |
1993年 | 174篇 |
1992年 | 185篇 |
1991年 | 124篇 |
1990年 | 118篇 |
1989年 | 97篇 |
1988年 | 115篇 |
1987年 | 109篇 |
1986年 | 111篇 |
1985年 | 121篇 |
1984年 | 135篇 |
1983年 | 75篇 |
1982年 | 76篇 |
1981年 | 55篇 |
1980年 | 69篇 |
1979年 | 51篇 |
1978年 | 58篇 |
1977年 | 54篇 |
1976年 | 59篇 |
1975年 | 65篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
《Research in social & administrative pharmacy》2022,18(8):3284-3289
BackgroundAdverse drug reactions (ADRs) and adverse drug events (ADEs) in older people contribute to a significant proportion of hospital admissions and are common following discharge. Effective interventions are therefore required to combat the growing burden of preventable ADRs. The Prediction of Hospitalisation due to Adverse Drug Reactions in Elderly Community Dwelling Patients (PADR-EC) score is a validated risk score developed to assess the risk of ADRs in people aged 65 years and older and has the potential to be utilised as part of an intervention to reduce ADRs.ObjectivesThis trial was designed to investigate the effectiveness of an intervention to reduce ADR incidence in older people and to obtain further information about ADRs and ADEs in the 12–24 months following hospital discharge.MethodsThe study is an open-label randomised-controlled trial to be conducted at the Royal Hobart Hospital, a 500-bed public hospital in Tasmania, Australia. Community-dwelling patients aged 65 years and older with an unplanned overnight admission to a general medical ward will be recruited. Following admission, the PADR-EC ADR score will be calculated by a research pharmacist, with the risk communicated to clinicians and discussed with participants. Following discharge, nominated general practitioners and community pharmacists will receive the risk score and related medication management advice to guide their ongoing care of the patient. Follow-up with participants will occur at 3 and 12 and 18 and 24 months to identify ADRs and ADEs. The primary outcome is moderate-severe ADRs at 12 months post-discharge, and will be analysed using the cumulative incidence proportion, survival analysis and Poisson regression.SummaryIt is hypothesised that the trial will reduce ADRs and ADEs in the intervention population. The study will also provide valuable data on post-discharge ADRs and ADEs up to 24 months post-discharge. 相似文献
5.
美国食品药品管理局(FDA)于2022年7月发布了"治疗等效性评价供企业用指导原则"(草案)。该指导原则阐明了FDA治疗等效性的标准以及治疗等效性编码系统,目的是准确评价仿制药与参比制剂的治疗等效性并通过治疗等效性代码,在"橙皮书"中迅速检索到治疗等效的仿制药。而中国目前尚无类似的指导原则,详细介绍FDA该指导原则主要内容,期望对中国加强仿制药的治疗等效性评价和加速完善和实施符合国情的治疗等效性编码系统有所帮助。 相似文献
6.
7.
8.
In the field of drug development, technology for producing human metabolites at a low cost is required. In this study, we explored the possibility of using prokaryotic water-soluble cytochrome P450 (CYP) to produce human metabolites. Streptomyces griseolus CYP105A1 metabolizes various non-steroidal anti-inflammatory drugs (NSAIDs), including diclofenac, mefenamic acid, flufenamic acid, tolfenamic acid, meclofenamic acid, and ibuprofen. CYP105A1 showed 4′-hydroxylation activity towards diclofenac, mefenamic acid, flufenamic acid, tolfenamic acid, and meclofenamic acid. It should be noted that this reaction specificity was similar to that of human CYP2C9. In the case of mefenamic acid, another metabolite, 3′-hydroxymethyl mefenamic acid, was detected as a major metabolite. Substitution of Arg at position 73 with Ala in CYP105A1 dramatically reduced the hydroxylation activity toward diclofenac, flufenamic acid, and ibuprofen, indicating that Arg73 is essential for the hydroxylation of these substrates. In contrast, substitution of Arg84 with Ala remarkably increased the hydroxylation activity towards diclofenac, mefenamic acid, and flufenamic acid. Recombinant Rhodococcus erythrocyte cells expressing the CYP105A1 variant R84A/M239A showed complete conversion of diclofenac into 4′-hydroxydiclofenac. These results suggest the usefulness of recombinant R. erythropolis cells expressing actinomycete CYP, such as CYP105A1, for the production of human drug metabolites. 相似文献
9.
10.
《Journal of the American Medical Directors Association》2022,23(3):379-386.e3
ObjectivesPreclinical and clinical studies indicate a role for MLC901 (NeuroAiD II) in Alzheimer's disease (AD). The primary aim was to investigate its safety as add-on therapy to standard treatment and the secondary aims its effect on cognition and slowing disease progression.DesignRandomized double-blind placebo-controlled delayed-start study.Setting and ParticipantPatients with mild to moderate probable AD by NINCDS-ADRDA criteria, stable on acetylcholinesterase inhibitors or memantine (n = 125), were randomized to receive MLC901 (early starters) or placebo (delayed starters) for 6 months, followed by a further 6 months when all patients received MLC901, in a delayed-start design (clinical trial registration: ClinicalTrials.gov, NCT03038035).MethodsThe primary outcome measure was occurrence of serious adverse events (SAEs) at 6 months. Secondary outcomes included the Alzheimer's Disease Assessment Scale–Cognitive subscale (ADAS-Cog) and other assessment scales.ResultsThere was no significant difference in the risk of SAEs between early and delayed starters at month (M) 6 (22.6% vs 27.0%, risk difference ?4.4%, 90% CI –16.9% to 8.3%). Similarly, there was no significant difference in the risk of adverse events and the occurrence of stroke or vascular events between early and delayed starters throughout the 12-month study period. Early starters did not differ significantly on ADAS-Cog from delayed starters at M6 [mean difference (MD) ?1.0, 95% CI –3.3 to 1.3] and M12 (MD –2.35, 95% CI –5.45 to 0.74) on intention-to-treat analysis. Other cognitive assessment scales did not show significant differences.Conclusions and ImplicationsThis study of 125 persons with dementia found no evidence of a significant increase in adverse events between MLC901 and placebo, thus providing support for further studies on both efficacy and safety. Analyses suggest the potential of MLC901 in slowing down AD progression, but this requires further confirmation in larger and longer studies using biomarkers for AD. 相似文献